Claims for Patent: 10,842,751

Summary for Patent: 10,842,751

Title:	Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
Abstract:	The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.
Inventor(s):	Panmai; Santipharp (Cranford, NJ), Tatavarti; Aditya (Chalfont, PA), Farrington; Andrew M. (Collegeville, PA), Biyyala; Varsha (Somerset, NJ), Allain; Leonardo R. (Lansdale, PA), Nefliu; Marcela (Schwenksville, PA), Klinzing; Gerard R. (Wilmington, DE), Ren; Jie (Chalfont, PA), Lamm; Matthew (Morristown, NJ)
Assignee:	MERCK SHARP & DOHME CORP. (Rahway, NJ)
Application Number:	16/791,398
Patent Claims:	1. A tablet comprising a first layer comprising an amorphous dispersion formulation of doravirine, and a second layer comprising lamivudine and tenofovir disoproxil fumarate. 2. The tablet of claim 1 wherein the first layer further comprises a polymer. 3. The tablet of claim 2 wherein the polymer is selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, cellulose acetate phthalate, cellulose acetate trimellitate, methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, cellulose acetate terephthalate, cellulose acetate isophthalate, polyvinylpyrrolidinone and polyvinylpyrrolidinone-polyvinylacetate copolymers. 4. The tablet of claim 3 wherein the polymer is hydroxypropyl methyl cellulose acetate succinate. 5. The tablet of claim 1 wherein the first layer further comprises microcrystalline cellulose. 6. The tablet of claim 1 wherein the first layer further comprises croscarmellose sodium. 7. The tablet of claim 1 wherein the second layer further comprises microcrystalline cellulose. 8. The tablet of claim 1 further comprising a film coat. 9. The tablet of claim 1 comprising 50 mg of doravirine, 150 mg of lamivudine and 150 mg of tenofovir disoproxil fumarate. 10. The tablet of claim 1 comprising 100 mg of doravirine, 300 mg of lamivudine and 300 mg of tenofovir disoproxil fumarate. 11. A tablet comprising (i) a first layer comprising an amorphous dispersion formulation of doravirine, hydroxypropyl methyl cellulose acetate succinate, microcrystalline cellulose, and croscarmellose sodium, and (ii) a second layer comprising lamivudine, tenofovir disoproxil fumarate and microcrystalline cellulose.